- Three abstracts from the Klario clinical programme in adults with type 1 diabetes were featured as e-posters at the inaugural Breakthrough T1D Clinical & Research Congress in Philadelphia.
- A new analysis of continuous glucose monitoring data found that participants spent around 35 fewer minutes a day at glucose extremes with Klario than with standard glucose gel, while overall time below range was unchanged.
- Higher glucose variability at the start of the study was strongly associated with a greater improvement in time in range after a hypoglycaemia episode. The authors suggest this supports a more personalised approach.
London, UK: Flow Health Science announced that three abstracts from the Klario® (FLO23011) clinical programme were featured as e-posters at the inaugural Breakthrough T1D Clinical & Research Congress, held in Philadelphia from 9 to 11 October 2026. The abstracts draw on a previously reported 12-week randomised, open-label, crossover study in 12 adults with type 1 diabetes, which compared Klario with standard glucose gel1. The research was led by Prof David Russell-Jones, Scientific Adviser to Flow Health Science.
Time at glucose extremes and glucose variability
A new AI-enabled biostatistical analysis of the study’s glucose monitoring data found that participants spent around 35 fewer minutes a day in combined glucose extremes (below 3.0 or above 10.0 mmol/L) with Klario than with standard glucose gel (p=0.0020). This reflected less time in hyperglycaemia and less time in severe hypoglycaemia (below 3.0 mmol/L; p=0.039), with no increase in overall time below range. Hyperglycaemia occurrence fell in all 12 participants.
Higher glucose variability at the start of the study was strongly associated with a greater improvement in time in range in the two hours after a hypoglycaemia episode (ρ=0.917; p=0.0005). The authors suggest this supports a more personalised approach to hypoglycaemia self-management.
Glucose response and recovery
In a pharmacokinetic study in six healthy adults, peak glucose did not differ significantly between Klario and standard glucose (7.4 vs 7.9 mmol/L; p=0.122). Across 1,032 hypoglycaemia episodes recorded by continuous glucose monitoring in the crossover study, time in range in the two hours after an episode was higher with Klario than with standard glucose gel (p=0.02).
Participant-reported recovery
Participants’ own accounts were collected through structured questionnaires and exit interviews. They rated Klario higher than standard glucose gel in 13 of 14 domains, covering perceived effectiveness, functional recovery, product characteristics and psychological outcomes. Two people living with type 1 diabetes contributed to this work as co-authors. These results were first presented at EASD 2026.
“For decades, hypo care has focused on one thing: bringing blood glucose back up. Our research looks at the glucose response and how people feel and function afterwards. Both need to be understood to move the standard of care forward.” — Prof David Russell-Jones, Scientific Adviser, Flow Health Science
The findings add to Flow Health Science’s ongoing research into recovery after hypoglycaemia.
“Being part of Breakthrough T1D’s first congress mattered to us. This is a community that puts people living with type 1 diabetes at the centre of research, and that is where we want our work to be tested and questioned.” — Georgia Myers, CEO, Flow Health Science
These findings should be interpreted in the context of the study design. The analyses come from an open-label study of 12 adults with type 1 diabetes.
About the Product
About Klario®
Klario® is a food product, not a medicine. It is a multi-substrate formulation providing glucose, BHB and lactate. More information: myklario.com.
References
1. Russell-Jones D, et al. Diabetes Obes Metab. 2026;28(5):3590–3597. doi:10.1111/dom.70323
About Flow Health Science
Flow Health Science is dedicated to transforming health outcomes through trusted, clinically-proven functional foods. Grounded in advanced metabolic science, our research and pipeline targets diabetes management, fatigue, hormone imbalances, and broader metabolic dysfunction.
Media Contact: Tara Lumley, Chief Strategy & Business Officer — press@flowhealthscience.com
Source: Flow Health Science